Physician profile
Wallace Hoke
NPI 1386605475
$16,351.63
in general payments reported to CMS, 2019-2025
59 companies · $2,530 in 2025
The $2,530 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,520 · 2020: $1,915 · 2021: $2,341 · 2022: $1,980 · 2023: $2,769 · 2024: $2,296 · 2025: $2,530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,595.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,997.25 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,902.78 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,595.37 | 2019-2025 | |
| Novo Nordisk INC | $1,433.29 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,075.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $971.20 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $669.23 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $562.44 | 2023-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $527.43 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $508.16 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $498.49 | 2019-2023 | Gardasil 9, Verquvo, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $472.96 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $415.36 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $407.86 | 2022-2025 | |
| Astellas Pharma US INC | $362.47 | 2019-2025 | Veozah, Myrbetriq |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Hoke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.